BACKGROUND

Diseases (e.g., related to nerve function) and nerve injury are not uncommon in the US and worldwide. However, effective treatments for diseases or nerve injury remain a challenge. For example, current treatments for nerve injuries (e.g., spinal or PNS injury), such as by transection or crushing, are limited or ineffective. There is a need to develop effective treatments for nerve injuries. In another example, there is no effective therapy to halt or slow the progression of multiple sclerosis (MS). MS is a prevalent demyelinating disease in the central nervous system (CNS) of both children and adults. There is a need for novel therapeutic modalities that can treat MS. And, more generally, there is a need to treat diseases (e.g., related to nerve function) and nerve injury.

Some embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising a myelination enhancing inhibitor to the animal. Other embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Still other embodiments of the invention include methods for treating an animal for MS or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Additional embodiments of the invention are also discussed herein.

SUMMARY

Some embodiments of the invention include methods for treating an animal for disease or nerve injury, comprising administration of a composition comprising a myelination enhancing inhibitor to the animal. In other embodiments, the myelination enhancing inhibitor is an HDAC3 (histone deacetylase 3) inhibitor, an HDAC (histone deacetylase) inhibitor, a demethylase inhibitor, or a methyltransferase inhibitor. In still other embodiments, the myelination enhancing inhibitor is an HDAC3 inhibitor. In some embodiments, the myelination enhancing inhibitor is CUDC-907, Quisinostat, RG2833, CUDC-101, Resminostat, 4SC-202, Mocetinostat, Entinostat, Citarinostat, Abexinostat, Pracinostat, apicidin, PDA106, RGFP966, CAY10398, chidamide, LAQ824, SAHA, GSK-J4, JIB-04, UNC0631, or UNC0646. In yet other embodiments, the myelination enhancing inhibitor is apicidin, PDA106, RGFP966, CAY10398, chidamide, LAQ824, SAHA, GSK-J4, JIB-04, UNC0631, or UNC0646. In some embodiments, the myelination enhancing inhibitor is CUDC-907, Quisinostat, RG2833, CUDC-101, Resminostat, 4SC-202, Mocetinostat, Entinostat, Citarinostat, Abexinostat, Pracinostat, apicidin, PDA106, or RGFP966. In yet other embodiments, the myelination enhancing inhibitor is PDA106 or RGFP966. In some embodiments, the method comprises more than one administration of the composition comprising the myelination enhancing inhibitor to the animal. In other embodiments, the amount of the myelination enhancing inhibitor is from about 0.0001% (by weight total composition) to about 99%. In still other embodiments, the composition further comprises a formulary ingredient. In yet other embodiments, the composition is a pharmaceutical composition. In some embodiments, the administration comprises parenteral administration, mucosal administration, intravenous administration, depot injection, subcutaneous administration, topical administration, intradermal administration, oral administration, sublingual administration, intranasal administration, or intramuscular administration. In other embodiments, the administration comprises a depot injection or an oral administration. In some embodiments, if there is more than one administration at least one composition used for at least one administration is different from the composition of at least one other administration. In other embodiments, the myelination enhancing inhibitor of the composition is administered to the animal in an amount of from about 0.005 mg/kg animal body weight to about 100 mg/kg animal body weight. In still other embodiments, the animal is a human, a rodent, or a primate. In yet other embodiments, the animal is in need of treatment of disease or nerve injury.

In some embodiments, the method is for treating myelopathy, spinal cord injury, myelitis, vascular myelopathy, cervical spondylotic myelopathy, spondylosis, spinal stenosis, demyelinating disease, any disease of the nervous system where the myelin sheath of a neuron is damaged, CNS demyelinating disease, PNS demyelinating disease, genetic demyelinating disease, infectious demyelinating disease, autoimmune demyelinating disease, demyelinating myelinoclastic disease, demyelinating leukodystrophic disease, Devic's disease, CNS neuropathies, diseases resulting in vitamin B12 deficiency, central pontine myelinolysis, myelopathies, tabesdorsalis, leukoencephalopathies, progressive multifocal leukoencephalopathy, leukodystrophies, optic neuritis, transverse myelitis, neuromyelitis optica, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, anti-MAG peripheral neuropathy, Charcot-Marie-Tooth disease, Hereditary neuropathy with liability to pressure palsy, copper deficiency associated conditions, peripheral neuropathy, myelopathy, optic neuropathy, progressive inflammatory neuropathy, multiple sclerosis (MS), MS-type clinically isolated syndrome, relapsing-remitting MS, primary progressive MS, secondary progressive MS, traumatic brain injury, acquired brain injury, hypoxic ischemic brain injury, strokes, periventricular leukomalacia (PVL), white-matter brain injury, CNS nerve injury, PNS nerve injury, crush nerve injury, or transection nerve injury. In still other embodiments, the method is for treating MS, MS-type clinically isolated syndrome, relapsing-remitting MS, primary progressive MS, or secondary progressive MS. In yet other embodiments, the method is for treating inflammation, remyelination, or both in MS, MS-type clinically isolated syndrome, relapsing-remitting MS, primary progressive MS, or secondary progressive MS. In some embodiments, the method is for treating inflammation and remyelination in MS, MS-type clinically isolated syndrome, relapsing-remitting MS, primary progressive MS, or secondary progressive MS. In other embodiments, the method is for treating CNS demyelinating disease, PNS demyelinating disease, MS, traumatic brain injury, acquired brain injury, hypoxic ischemic brain injury, strokes, periventricular leukomalacia (PVL), white-matter brain injury, CNS nerve injury, PNS nerve injury, crush nerve injury, or transection nerve injury. In yet other embodiments, the method is for treating CNS demyelinating disease, PNS demyelinating disease, MS, CNS nerve injury, PNS nerve injury, crush nerve injury, or transection nerve injury. In still other embodiments, the method is for treating CNS nerve injury, PNS nerve injury, crush nerve injury, or transection nerve injury. In yet other embodiments, the method is for treating crush nerve injury or transection nerve injury. In some embodiments, the method further comprises one or more other treatments.

Some embodiments of the invention include methods for treating an animal for MS or nerve injury, comprising administration of a composition comprising an HDAC3 inhibitor to the animal.

Other embodiments of the invention include methods for treating an animal for MS or nerve injury, comprising administration of a composition comprising PDA106 or RGFP966 to the animal.

Other embodiments of the invention are also discussed herein.

